277 related articles for article (PubMed ID: 28233412)
21. Elucidation of the physicochemical properties and potency of siRNA-loaded small-sized lipid nanoparticles for siRNA delivery.
Sato Y; Note Y; Maeki M; Kaji N; Baba Y; Tokeshi M; Harashima H
J Control Release; 2016 May; 229():48-57. PubMed ID: 26995758
[TBL] [Abstract][Full Text] [Related]
22. Mechanism of macromolecular structure evolution in self-assembled lipid nanoparticles for siRNA delivery.
Gindy ME; DiFelice K; Kumar V; Prud'homme RK; Celano R; Haas RM; Smith JS; Boardman D
Langmuir; 2014 Apr; 30(16):4613-22. PubMed ID: 24684657
[TBL] [Abstract][Full Text] [Related]
23. Ionizable amino lipid interactions with POPC: implications for lipid nanoparticle function.
Ramezanpour M; Schmidt ML; Bodnariuc I; Kulkarni JA; Leung SSW; Cullis PR; Thewalt JL; Tieleman DP
Nanoscale; 2019 Aug; 11(30):14141-14146. PubMed ID: 31334542
[TBL] [Abstract][Full Text] [Related]
24. Next-Generation Lipids in RNA Interference Therapeutics.
Rietwyk S; Peer D
ACS Nano; 2017 Aug; 11(8):7572-7586. PubMed ID: 28727419
[TBL] [Abstract][Full Text] [Related]
25. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells.
Basha G; Novobrantseva TI; Rosin N; Tam YY; Hafez IM; Wong MK; Sugo T; Ruda VM; Qin J; Klebanov B; Ciufolini M; Akinc A; Tam YK; Hope MJ; Cullis PR
Mol Ther; 2011 Dec; 19(12):2186-200. PubMed ID: 21971424
[TBL] [Abstract][Full Text] [Related]
26. Incorporation of mRNA in Lamellar Lipid Matrices for Parenteral Administration.
Ziller A; Nogueira SS; Hühn E; Funari SS; Brezesinski G; Hartmann H; Sahin U; Haas H; Langguth P
Mol Pharm; 2018 Feb; 15(2):642-651. PubMed ID: 29232147
[TBL] [Abstract][Full Text] [Related]
27. How does the spacer length of cationic gemini lipids influence the lipoplex formation with plasmid DNA? Physicochemical and biochemical characterizations and their relevance in gene therapy.
Muñoz-Úbeda M; Misra SK; Barrán-Berdón AL; Datta S; Aicart-Ramos C; Castro-Hartmann P; Kondaiah P; Junquera E; Bhattacharya S; Aicart E
Biomacromolecules; 2012 Dec; 13(12):3926-37. PubMed ID: 23130552
[TBL] [Abstract][Full Text] [Related]
28. Acidic pH-induced changes in lipid nanoparticle membrane packing.
Koitabashi K; Nagumo H; Nakao M; Machida T; Yoshida K; Sakai-Kato K
Biochim Biophys Acta Biomembr; 2021 Aug; 1863(8):183627. PubMed ID: 33901441
[TBL] [Abstract][Full Text] [Related]
29. Amphiphilic brush polymers produced using the RAFT polymerisation method stabilise and reduce the cell cytotoxicity of lipid lyotropic liquid crystalline nanoparticles.
Zhai J; Suryadinata R; Luan B; Tran N; Hinton TM; Ratcliffe J; Hao X; Drummond CJ
Faraday Discuss; 2016 Oct; 191():545-563. PubMed ID: 27453499
[TBL] [Abstract][Full Text] [Related]
30. Stabilization of Ostwald ripening in low molecular weight amino lipid nanoparticles for systemic delivery of siRNA therapeutics.
Gindy ME; Feuston B; Glass A; Arrington L; Haas RM; Schariter J; Stirdivant SM
Mol Pharm; 2014 Nov; 11(11):4143-53. PubMed ID: 25317715
[TBL] [Abstract][Full Text] [Related]
31. Development of a Microfluidic-Based Post-Treatment Process for Size-Controlled Lipid Nanoparticles and Application to siRNA Delivery.
Kimura N; Maeki M; Sato Y; Ishida A; Tani H; Harashima H; Tokeshi M
ACS Appl Mater Interfaces; 2020 Jul; 12(30):34011-34020. PubMed ID: 32667806
[TBL] [Abstract][Full Text] [Related]
32. Cuboplexes: Topologically Active siRNA Delivery.
Kim H; Leal C
ACS Nano; 2015 Oct; 9(10):10214-26. PubMed ID: 26390340
[TBL] [Abstract][Full Text] [Related]
33. Compression of Vectors for Small Interfering RNAs Delivery: Toward Oral Administration of siRNA Lipoplexes in Tablet Forms.
Busignies V; Arruda DC; Charrueau C; Ribeiro MCS; Lachagès AM; Malachias A; Finet S; Rehman AU; Bigey P; Tchoreloff P; Escriou V
Mol Pharm; 2020 Apr; 17(4):1159-1169. PubMed ID: 32125867
[TBL] [Abstract][Full Text] [Related]
34. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery.
Cheng X; Lee RJ
Adv Drug Deliv Rev; 2016 Apr; 99(Pt A):129-137. PubMed ID: 26900977
[TBL] [Abstract][Full Text] [Related]
35. Enhanced Delivery of siRNA to Retinal Ganglion Cells by Intravitreal Lipid Nanoparticles of Positive Charge.
Huang X; Chau Y
Mol Pharm; 2021 Jan; 18(1):377-385. PubMed ID: 33295773
[TBL] [Abstract][Full Text] [Related]
36. Influence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNA.
Lin PJ; Tam YY; Hafez I; Sandhu A; Chen S; Ciufolini MA; Nabi IR; Cullis PR
Nanomedicine; 2013 Feb; 9(2):233-46. PubMed ID: 22698807
[TBL] [Abstract][Full Text] [Related]
37. Development of Lipid Nanoparticles for the Delivery of Macromolecules Based on the Molecular Design of pH-Sensitive Cationic Lipids.
Sato Y
Chem Pharm Bull (Tokyo); 2021; 69(12):1141-1159. PubMed ID: 34853281
[TBL] [Abstract][Full Text] [Related]
38. Effects of cationic lipids in cationic liposomes and disaccharides in the freeze-drying of siRNA lipoplexes on gene silencing in cells by reverse transfection.
Hattori Y; Hu S; Onishi H
J Liposome Res; 2020 Sep; 30(3):235-245. PubMed ID: 31185779
[TBL] [Abstract][Full Text] [Related]
39. Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation.
Chen D; Love KT; Chen Y; Eltoukhy AA; Kastrup C; Sahay G; Jeon A; Dong Y; Whitehead KA; Anderson DG
J Am Chem Soc; 2012 Apr; 134(16):6948-51. PubMed ID: 22475086
[TBL] [Abstract][Full Text] [Related]
40. Chitosan-lipid nanoparticles (CS-LNPs): Application to siRNA delivery.
Tezgel Ö; Szarpak-Jankowska A; Arnould A; Auzély-Velty R; Texier I
J Colloid Interface Sci; 2018 Jan; 510():45-56. PubMed ID: 28934610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
